BRAF and breast carcinoma: This is epitomized by the application of ErbB2‐targeted drugs in a subset of breast cancers, of BRAF inhibitors in melanomas, of drugs targeting liabilities due to mutated BRCA in gynecological tumors, to cite some key examples.